Expert Opinion on Therapeutic Targets最新文献_第3页

Sirtuins as therapeutic targets in diabetes. Sirtuins作为糖尿病的治疗靶点。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-03-01 Epub Date: 2025-03-31 DOI: 10.1080/14728222.2025.2482563

Kajetan Kielbowski, Aleksandra Wiktoria Bratborska, Estera Bakinowska, Andrzej Pawlik

{"title":"Sirtuins as therapeutic targets in diabetes.","authors":"Kajetan Kielbowski, Aleksandra Wiktoria Bratborska, Estera Bakinowska, Andrzej Pawlik","doi":"10.1080/14728222.2025.2482563","DOIUrl":"10.1080/14728222.2025.2482563","url":null,"abstract":"Introduction: Sirtuins (SIRTs) are NAD+-dependent deacetylases that mediate post-translational modifications of proteins. Seven members of the SIRT family have been identified in mammals. Importantly, SIRTs interact with numerous metabolic and inflammatory pathways. Thus, researchers have investigated their role in metabolic and inflammatory disorders.Areas covered: In this review, we comprehensively discuss the involvement of SIRTs in the processes of pancreatic β-cell dysfunction, glucose tolerance, insulin secretion, lipid metabolism, and adipocyte functions. In addition, we describe the current evidence regarding modulation of the expression and activity of SIRTs in diabetes, diabetic complications, and obesity.Expert opinion: The development of specific SIRT activators and inhibitors that exhibit high selectivity toward specific SIRT isoforms remains a major challenge. This involves the need to elucidate the physiological pathways involving SIRTs, as well as their important role in the development of metabolic disorders. Molecular modeling techniques will be helpful to develop new compounds that modulate the activity of SIRTs, which may contribute to the preparation of new drugs that selectively target specific SIRTs. SIRTs hold promise as potential targets in metabolic disease, but there is much to learn about specific modulators and the final answers will await clinical trials.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"117-135"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential role of indole-3-propionic acid in tuberculosis: current perspectives and future prospects. 吲哚-3-丙酸在结核病中的潜在作用：目前的观点和未来的展望。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-03-01 Epub Date: 2025-03-31 DOI: 10.1080/14728222.2025.2482548

Tejaswini Baral, Aieshel Serafin Johnson, Mazhuvancherry Kesavan Unnikrishnan, Mohan K Manu, Kavitha Saravu, Chandrashekar Udyavara Kudru, Suhaj Abdulsalim, Jitendra Singh, Chiranjay Mukhopadhyay, Mahadev Rao, Sonal Sekhar Miraj

{"title":"Potential role of indole-3-propionic acid in tuberculosis: current perspectives and future prospects.","authors":"Tejaswini Baral, Aieshel Serafin Johnson, Mazhuvancherry Kesavan Unnikrishnan, Mohan K Manu, Kavitha Saravu, Chandrashekar Udyavara Kudru, Suhaj Abdulsalim, Jitendra Singh, Chiranjay Mukhopadhyay, Mahadev Rao, Sonal Sekhar Miraj","doi":"10.1080/14728222.2025.2482548","DOIUrl":"10.1080/14728222.2025.2482548","url":null,"abstract":"Introduction: Indole-3-propionic acid (IPA), a tryptophan catabolite derived from gut bacterial metabolism, has been identified as a functional link between the gut microbiome and tuberculosis.Area covered: IPA has gained ample attention over the past two decades on account of its multiple physiological roles, besides being both detectable and quantifiable. IPA is well studied across different health conditions, including cardiovascular and neurological conditions. IPA blocks tryptophan synthesis in Mycobacterium by binding to the allosteric tryptophan-binding site of TrpE, thereby threatening Mycobacterium survival due to tryptophan deficit.Expert opinion: Characterizing IPA would enable its use as a tool to investigate the pathophysiology of tuberculosis. Integrating 'OMICS' techniques (through next-generation sequencing) along with targeted microbial metabolomics may help explore the possible association of serum IPA levels with TB in patients. This will aid in identifying IPA-producing gut microbes and selecting probiotic strains as a microbiome-targeting adjunct therapy, eventually enhancing our understanding of the molecular dynamics of the pathophysiology of tuberculosis in the context of the microbiome.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"171-178"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic targeting of the polyglutamine androgen receptor in Spinal and Bulbar Muscular Atrophy. 多谷氨酰胺雄激素受体治疗脊髓和球性肌萎缩的靶向性研究。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-01-01 Epub Date: 2025-02-10 DOI: 10.1080/14728222.2025.2464173

Agamjot Sangotra, Andrew P Lieberman

{"title":"Therapeutic targeting of the polyglutamine androgen receptor in Spinal and Bulbar Muscular Atrophy.","authors":"Agamjot Sangotra, Andrew P Lieberman","doi":"10.1080/14728222.2025.2464173","DOIUrl":"10.1080/14728222.2025.2464173","url":null,"abstract":"Introduction: Spinal and Bulbar Muscular Atrophy (SBMA) is a slowly progressive, X-linked, and sex-limited degenerative disorder affecting lower motor neurons and skeletal muscle which lacks disease-modifying therapies. This disease is caused by a CAG/polyglutamine (polyQ) tract expansion in the androgen receptor (AR) gene, and its pathogenesis is driven by toxic gain-of-function mechanisms. Affected men develop proximal limb and bulbar muscle weakness along with signs of partial androgen insensitivity.Areas covered: Toxicity of the polyQ AR is mediated by protein misfolding and nuclear translocation that follow ligand binding, resulting in the disruption of downstream homeostatic mechanisms. This review highlights what is known about disease pathogenesis and how this has been leveraged to test potential therapeutic approaches. The focus is on strategies that alleviate polyQ AR toxicity in SBMA, including those that alter AR function, diminish the expression of the encoding gene, or promote clearance of the misfolded, mutant protein.Expert opinion: We discuss emerging strategies to mitigate polyQ AR toxicity, including gene editing, RNA targeted therapies, and efforts to harness proteostatic mechanisms. These promising approaches are discussed in the context of challenges for drug discovery efforts that are faced when attempting to treat a rare and slowly progressive neurodegenerative disorder.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"29-41"},"PeriodicalIF":4.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting acid-sensing ion channels in glioblastoma: is there any therapeutic potential? 以胶质母细胞瘤中的酸感应离子通道为靶点：是否有治疗潜力？

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-01-01 Epub Date: 2025-02-06 DOI: 10.1080/14728222.2025.2463357

Andrea Menegon

引用次数: 0

Assessing platelet-derived extracellular vesicles for potential as therapeutic targets in cardiovascular diseases. 评估血小板来源的细胞外囊泡作为心血管疾病治疗靶点的潜力。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-01-01 Epub Date: 2025-01-18 DOI: 10.1080/14728222.2025.2454617

Xin Xin, Rory R Koenen

{"title":"Assessing platelet-derived extracellular vesicles for potential as therapeutic targets in cardiovascular diseases.","authors":"Xin Xin, Rory R Koenen","doi":"10.1080/14728222.2025.2454617","DOIUrl":"10.1080/14728222.2025.2454617","url":null,"abstract":"Introduction: Cardiovascular disease (CVD) is the leading cause of death worldwide. Platelet-derived extracellular vesicles (PEV) have attracted extensive attention in cardiovascular disease research in recent years because their cargo is involved in a variety of pathophysiological processes, such as thrombosis, immune response, promotion or inhibition of inflammatory response, promotion of angiogenesis as well as cell proliferation and migration.Areas covered: This review explores the role of PEV in various cardiovascular diseases (such as atherosclerosis, myocardial infarction, ischemia-reperfusion injury, and heart failure), with relation to its molecular cargo (nucleic acids, bioactive lipids, proteins) and aims to provide new insights in the pathophysiologic role of PEV, and methods for preventing and treating cardiovascular diseases based on PEV.Expert opinion: Studies have shown that the cargo of PEV may be dysregulated during cardiovascular disease and delivery to tissues can result in detrimental pathophysiologic effects. Counteracting this process might have the potential to inhibit inflammation, promote angiogenesis, and inhibit cardiomyocyte death. In addition, PEV have potential as biocompatible and autologous drug carriers. Therefore, better research on the mechanisms how PEV act during cardiovascular disease and could be implemented as a therapeutic will provide new perspectives for the treatment of cardiovascular disease.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"17-28"},"PeriodicalIF":4.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting glypican 3 by immunotoxins: the promise of immunotherapy in hepatocellular carcinoma. 免疫毒素靶向glypican 3的研究肝细胞癌免疫治疗的前景。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-01-01 Epub Date: 2025-02-26 DOI: 10.1080/14728222.2025.2471581

Elham Rismani, Nikoo Hossein-Khannazer, Moustapha Hassan, Elahe Shams, Mustapha Najimi, Massoud Vosough

{"title":"Targeting glypican 3 by immunotoxins: the promise of immunotherapy in hepatocellular carcinoma.","authors":"Elham Rismani, Nikoo Hossein-Khannazer, Moustapha Hassan, Elahe Shams, Mustapha Najimi, Massoud Vosough","doi":"10.1080/14728222.2025.2471581","DOIUrl":"10.1080/14728222.2025.2471581","url":null,"abstract":"Introduction: Tumor cell's resistance, high recurrence rate, and low overall survival rate have made hepatocellular carcinoma (HCC) a major health concern. The combination of advanced targeted therapies such as immunotherapy, with conventional treatments has gained traction for application on HCC. Immunotoxins (ITs) represent a category of biomolecules that combine the targeted affinity of antibodies with the cytotoxic properties of toxins.Areas covered: This study highlights Glypican3 (GPC3) as a potential candidate for targeted therapeutic interventions using ITs. It presents a comprehensive overview of the advantages and challenges associated with these modalities, and their promising outcomes in HCC treatment. A systematic literature review was conducted using PubMed, Web of Science and Scopus from 2015 to 2024.Expert opinion: Despite potential applicability, many concerns should be addressed before the employment of GPC3-based ITs. These include improving efficient penetration of ITs into the solid tumors, considering neutralizing antibodies against the drugs, and enhancing serum half-life of ITs. Furthermore, the ITs potential in eliminating cancer stem cells (CSCs) and residual tumor cells is discussed. The ability to target CSCs can significantly reduce the likelihood of recurrence and improve overall survival rate. This could make ITs a pivotal component in the future of HCC treatment.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"59-73"},"PeriodicalIF":4.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NF-κB-inducing kinase (NIK): an emerging therapeutic target in human disease. nf - kb诱导激酶（NIK）：人类疾病新出现的治疗靶点。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-01-01 Epub Date: 2025-02-09 DOI: 10.1080/14728222.2025.2464175

Cassandra S Poole, Irving Coy Allen

引用次数: 0

Mast cell chymase-1 and tryptases: therapeutic targets for COPD? 肥大细胞乳糜酶-1和胰蛋白酶：COPD的治疗靶点？

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-01-01 Epub Date: 2025-02-23 DOI: 10.1080/14728222.2025.2464176

Gang Liu, Angelica Tiotiu, Philip M Hansbro

引用次数: 0

Pharmacological targeting of ECM homeostasis, fibroblast activation and invasion for the treatment of pulmonary fibrosis. ECM稳态、成纤维细胞激活和侵袭的药物靶向治疗肺纤维化。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-01-01 Epub Date: 2025-02-27 DOI: 10.1080/14728222.2025.2471579

Ioannis Tomos, Paraskevi Kanellopoulou, Dimitris Nastos, Vassilis Aidinis

{"title":"Pharmacological targeting of ECM homeostasis, fibroblast activation and invasion for the treatment of pulmonary fibrosis.","authors":"Ioannis Tomos, Paraskevi Kanellopoulou, Dimitris Nastos, Vassilis Aidinis","doi":"10.1080/14728222.2025.2471579","DOIUrl":"10.1080/14728222.2025.2471579","url":null,"abstract":"Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease with a dismal prognosis. While the standard-of-care (SOC) drugs approved for IPF represent a significant advancement in antifibrotic therapies, they primarily slow disease progression and have limited overall efficacy and many side effects. Consequently, IPF remains a condition with high unmet medical and pharmacological needs.Areas covered: A wide variety of molecules and mechanisms have been implicated in the pathogenesis of IPF, many of which have been targeted in clinical trials. In this review, we discuss the latest therapeutic targets that affect extracellular matrix (ECM) homeostasis and the activation of lung fibroblasts, with a specific focus on ECM invasion.Expert opinion: A promising new approach involves targeting ECM invasion by fibroblasts, a process that parallels cancer cell behavior. Several cancer drugs are now being tested in IPF for their ability to inhibit ECM invasion, offering significant potential for future treatments. The delivery of these therapies by inhalation is a promising development, as it may enhance local effectiveness and minimize systemic side effects, thereby improving patient safety and treatment efficacy.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"43-57"},"PeriodicalIF":4.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential of multimolecular G-quadruplex structures for targeted treatment of Amyotrophic Lateral Sclerosis. 多分子g -四重结构靶向治疗肌萎缩性侧索硬化症的潜力。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2025-01-01 Epub Date: 2025-02-07 DOI: 10.1080/14728222.2025.2463361

Nereida Abad-Yang, Federica Raguseo, Lorenzo Di Michele, Rickie Patani, Marco Di Antonio

引用次数: 0